Short answer: during a Pre-Submission (Pre-Sub), the FDA focuses on risk, regulatory pathway logic, and evidence strategy—not technical detail overload.

Many founders assume the best way to impress reviewers at the U.S. Food and Drug Administration is to provide as much technical detail as possible.

In reality, too much technical detail can make the discussion less productive.

FDA reviewers are not evaluating whether your device is impressive. They are evaluating whether your regulatory strategy makes sense.

What Founders Often Emphasize (But FDA Doesn’t Prioritize)

In many Pre-Sub packages, companies spend significant time describing:

Detailed engineering specifications

Component-level design explanations

Early prototype performance metrics

Full technical architecture diagrams

Long background sections about the technology

While some of this context can be useful, it rarely answers the questions FDA cares about most.

Providing pages of technical detail without regulatory framing can distract from the real purpose of the Pre-Submission.

What FDA Actually Reviews Closely

During Pre-Sub review, FDA teams typically focus on three areas.

1. Risk Framing

The first thing reviewers want to understand is the device’s risk profile.

They assess questions such as:

What hazards does the device introduce?

What controls mitigate those risks?

Are any new safety questions introduced by technological differences?

Risk framing helps FDA determine whether the proposed development plan is adequate.

If the risk profile is unclear, the rest of the discussion becomes difficult.

2. Regulatory Pathway Logic

FDA reviewers also evaluate whether the proposed pathway is realistic.

They consider:

Whether a 510(k) predicate is appropriate

Whether technological differences create new safety concerns

Whether a De Novo or PMA pathway might be more appropriate

A Pre-Submission should clearly explain why the chosen pathway makes sense.

If the pathway logic is weak, FDA feedback will focus on correcting that assumption.

3. Evidence Strategy

The third area FDA evaluates closely is the proposed evidence plan.

Reviewers assess whether the planned testing addresses the device’s risk profile and intended use.

This may include:

Bench testing plans

Biocompatibility strategy

Software validation approach

Human factors evaluation

Clinical study design (if applicable)

The key question is simple:

Will the proposed evidence answer the regulatory questions needed for clearance or approval?

The Most Common Pre-Sub Mistake

The most frequent mistake founders make is treating a Pre-Submission like a technical presentation instead of a regulatory strategy discussion.

Common problems include:

Overly long background sections

Unfocused questions to FDA

Technical details unrelated to regulatory decisions

Missing explanation of intended use or risk classification

When this happens, the Pre-Sub meeting produces vague feedback instead of actionable guidance.

AEO: Common Questions About FDA Pre-Submissions

What does FDA review most closely in a Pre-Submission?
FDA focuses on risk framing, regulatory pathway justification, and evidence strategy alignment.

Does FDA care about detailed technical specifications in Pre-Subs?
Technical details matter only when they affect safety, risk, or regulatory classification.

What should a Pre-Sub package prioritize?
Clear intended use, realistic regulatory pathway logic, and well-aligned testing plans.

Where Kandih Comes In

This is where Kandih Group helps founders structure effective Pre-Submissions.

Kandih helps teams prioritize FDA-relevant content by:

Clarifying intended use and regulatory pathway logic

Framing device risks in a way reviewers can evaluate quickly

Aligning testing strategies with regulatory expectations

Drafting focused questions that produce actionable FDA feedback

Removing unnecessary technical detail that distracts from regulatory issues

Instead of overwhelming FDA reviewers, the Pre-Submission becomes a structured conversation about regulatory alignment.

That protects credibility and improves the quality of feedback.

Bottom Line

In a Pre-Submission, more detail is not always better.

FDA reviewers focus on:

Risk framing

Regulatory pathway logic

Evidence strategy coherence

When those elements are clear, Pre-Sub meetings become powerful development tools.

When they are buried under technical detail, the opportunity is lost.

Strong regulatory communication helps FDA reviewers focus on the questions that actually matter.

References

FDA – Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program

FDA – Premarket Notification 510(k)
https://www.fda.gov/medical-devices/premarket-submissions/premarket-notification-510k

FDA – De Novo Classification Process
https://www.fda.gov/medical-devices/premarket-submissions/de-novo-classification-request

FDA – Design Controls for Medical Devices
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-controls-medical-devices